Novabridge Biosciences Quick Ratio (NBP) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Novabridge Biosciences  (NBP)

Novabridge Biosciences's Quick Ratio

NBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 7.33 below Novabridge Biosciences average.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Quick Ratio than Novabridge Biosciences in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 426.

Explain Quick Ratio?
How much Cash & cash equivalents NBP´s has?
What are NBP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBP Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 183.28 % -68.69 % -85.73 % 240.44 % -85.42 %
Y / Y Cash & cash equivalent Change 21.59 % -81.4 % -86.56 % 21.59 % -44.5 %
Quick Ratio MRQ 7.33 13.49 21.38 8.11 17.07
NBP's Total Ranking # 426 # # # #
Seq. Current Liabilities Change 1103.62 % 119.42 % -95.81 % 155.94 % 33.02 %
Seq. Cash & cash equivalent Change 553.85 % 38.4 % -88.95 % 21.59 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 151
Overall Market # 426


Quick Ratio Statistics
High Average Low
22.7 8.62 0.4
0   (Dec 31 2022)




Financial Statements
Novabridge Biosciences's Current Liabilities $ 29 Millions Visit NBP's Balance sheet
Novabridge Biosciences's Cash & cash equivalent $ 211 Millions Visit NBP's Balance sheet
Source of NBP's Sales Visit NBP's Sales by Geography


Cumulative Novabridge Biosciences's Quick Ratio

NBP's Quick Ratio for the trailling 12 Months

NBP Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 76.17 % -57.19 % -67.84 % -72.43 % -85.92 %
Y / Y Cash & cash equivalent TTM Growth -31.19 % -47.18 % -40.78 % -35.27 % -45.72 %
Quick Ratio TTM 8.19 11.09 12.94 14.21 20.97
Total Ranking TTM # 4039 # # # #
Seq. Current Liabilities TTM Growth 46.97 % -11.69 % -12.73 % 55.53 % -64.29 %
Seq. Cash & cash equivalent TTM Growth 8.51 % -24.3 % -20.53 % 5.4 % -16.7 %

Quick ratio ranking by company, industry and sector >> Back to NBP Financial Strength Comparisons >> Go to Compare NBP Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2025 to $28.78 millions, cumulative Quick Ratio decreased to 8.19 above the NBP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 466 other companies have achieved higher Quick Ratio than Novabridge Biosciences. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4039.

Explain Quick Ratio?
How much Cash & cash equivalents NBP´s has?
What are NBP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 467
Healthcare Sector # 940
Within the Market # 4039


trailing twelve months Quick Ratio Statistics
High Average Low
20.51 7.65 1.99
(Dec 31 2024)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Siga Technologies Inc  19.99 $ 154.966  Millions$ 7.753  Millions
Trevi Therapeutics Inc   19.94 $ 188.260  Millions$ 9.442  Millions
Edgewise Therapeutics inc   19.37 $ 530.109  Millions$ 27.370  Millions
Maplight Therapeutics Inc   18.80 $ 305.103  Millions$ 16.229  Millions
Kezar Life Sciences Inc   16.92 $ 71.878  Millions$ 4.248  Millions
Stoke Therapeutics Inc   16.90 $ 284.670  Millions$ 16.840  Millions
Design Therapeutics Inc   16.84 $ 219.845  Millions$ 13.055  Millions
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions
Xbiotech Inc   15.83 $ 125.551  Millions$ 7.929  Millions
Tango Therapeutics Inc   15.83 $ 343.138  Millions$ 21.679  Millions
Mira Pharmaceuticals Inc   15.71 $ 11.030  Millions$ 0.702  Millions
Phio Pharmaceuticals Corp  15.69 $ 21.031  Millions$ 1.340  Millions
Alto Neuroscience Inc   15.58 $ 176.484  Millions$ 11.325  Millions
Veradermics Inc  15.50 $ 141.862  Millions$ 9.152  Millions
Ocular Therapeutix Inc   15.36 $ 737.060  Millions$ 47.989  Millions
Nuvalent Inc   15.05 $ 1,371.952  Millions$ 91.171  Millions
Mereo Biopharma Group Plc  14.66 $ 41.387  Millions$ 2.824  Millions
Bioharvest Sciences Inc   14.57 $ 46.050  Millions$ 3.160  Millions
Immunome Inc   14.55 $ 654.782  Millions$ 44.990  Millions
Eupraxia Pharmaceuticals Inc   14.51 $ 80.563  Millions$ 5.551  Millions
Climb Bio Inc   14.47 $ 101.080  Millions$ 6.984  Millions
Synlogic Inc   14.41 $ 14.668  Millions$ 1.018  Millions
Cervomed Inc   14.35 $ 20.864  Millions$ 1.454  Millions
Bicara Therapeutics Inc   14.33 $ 414.801  Millions$ 28.949  Millions
Tyra Biosciences Inc   14.15 $ 256.003  Millions$ 18.094  Millions
Rezolute Inc   14.09 $ 167.858  Millions$ 11.912  Millions
Cogent Biosciences Inc   14.08 $ 900.765  Millions$ 63.953  Millions
Keros Therapeutics Inc   14.08 $ 287.415  Millions$ 20.414  Millions
Amylyx Pharmaceuticals Inc   13.97 $ 316.979  Millions$ 22.688  Millions
Oric Pharmaceuticals Inc   13.79 $ 281.488  Millions$ 20.417  Millions

Date modified: 2026-07-07T12:24:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.